# acquired hypothalamic obesity FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/acquired-hypothalamic-obesity

> No upcoming FDA catalysts in acquired hypothalamic obesity; 6 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for acquired hypothalamic obesity?

No upcoming FDA catalysts in acquired hypothalamic obesity; 6 past events are recorded. Press release filed with the SEC (EX-99): "-- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity --" [Calendar and source filings](https://sec-api.dev/indications/acquired-hypothalamic-obesity)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-021801, https://www.sec.gov/Archives/edgar/data/1649904/000110465926021801/tm267699d1_ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-03-02. Cite: https://sec-api.dev/indications/acquired-hypothalamic-obesity#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Q1 2025 | [RM-718 trial start](https://sec-api.dev/pdufa/rm-718) | RYTM | acquired hypothalamic obesity | scheduled | "With RM-718, we anticipate initiating Part C of our Phase 1 trial to evaluate this weekly MC4R agonist in patients with acquired hypothalamic obesity in the first quarter of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1649904/000155837025001889/rytm-20241231x10k.htm)) |
| Q2 2025 | [IMCIVREE® (setmelanotide) topline data readout](https://sec-api.dev/pdufa/setmelanotide) | RYTM | acquired hypothalamic obesity - | scheduled | ""Our global trial of setmelanotide in patients with acquired hypothalamic obesity - which is on track for topline data readout in the second quarter of 2025 - is being conducted in North America, Europe and Japan, and this reacquisition of rights for China, Hong Kong and Macau means Rhythm now owns the global franchise." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000155837025003374/rytm-20250314xex99d1.htm)) |
| April 7, 2025 | [IMCIVREE® (setmelanotide) topline data readout](https://sec-api.dev/pdufa/setmelanotide) | RYTM | acquired hypothalamic obesity | completed, positive | "BOSTON, April 7, 2025 - Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced positive topline results from the pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, for the treatment of acquired hypothalamic obesity." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000155837025004507/rytm-20250407xex99d1.htm)) |
| Q3 2025 | [RM-718 topline data readout](https://sec-api.dev/pdufa/rm-718) | RYTM | acquired hypothalamic obesity | scheduled | "We anticipate reading out topline data from our Phase 2 trial evaluating bivamelagon in patients with acquired hypothalamic obesity in the third quarter of 2025, and we anticipate completing enrollment in Part C of the Phase 1 trial evaluating the weekly RM-718 in patients with acquired hypothalamic obesity." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1649904/000155837025006765/rytm-20250331x10q.htm)) |
| Mar 2026 | [IMCIVREE® (setmelanotide) topline data readout](https://sec-api.dev/pdufa/setmelanotide) | RYTM | acquired hypothalamic obesity | scheduled | "A supplemental cohort of 12 Japanese patients remains ongoing with completion and topline data anticipated in the first quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000155837025004507/rytm-20250407xex99d1.htm)) |
| March 20, 2026 | [IMCIVREE® (setmelanotide) PDUFA date](https://sec-api.dev/pdufa/setmelanotide) | RYTM | acquired hypothalamic obesity | completed, approved | "-- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity --" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000110465926021801/tm267699d1_ex99-1.htm)) |

## Drugs

- [RM-718](https://sec-api.dev/pdufa/rm-718) (RYTM)
- [IMCIVREE® (setmelanotide)](https://sec-api.dev/pdufa/setmelanotide) (RYTM)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/acquired-hypothalamic-obesity.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "acquired hypothalamic obesity FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/acquired-hypothalamic-obesity

```bibtex
@misc{secapidev_indications_acquired_hypothalamic_obesity_20261116,
  title        = {acquired hypothalamic obesity FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/acquired-hypothalamic-obesity}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_acquired_hypothalamic_obesity_20261116","title":"acquired hypothalamic obesity FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/acquired-hypothalamic-obesity","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
